Skip to main content
. Author manuscript; available in PMC: 2018 Nov 15.
Published in final edited form as: Clin Cancer Res. 2017 Sep 12;23(22):7072–7083. doi: 10.1158/1078-0432.CCR-17-0413

Figure 3. Patients with concurrent TOP2A and EZH2 expression develop an aggressive, metastatic disease.

Figure 3

(A) Example of fluorescence immunohistochemistry for alpha-methylacyl-CoA racemase (AMACR; tumor epithelial cells) with 4′,6-diamidino-2-phenylindole (DAPI; cell nucleus), TOP2A and EZH2 on a representative TOP2A+/EZH2+ prostate tumor microarray core. (B, C) High expression of TOP2A and EZH2 proteins (TOP2A+/EZH2+) is associated to decreased time to BCR (B) and to metastatic event (C). (D) Multivariate CoxPH model of assessing the associations of marker groups (Others vs. TOP2A+/EZH2+) adjusting for clinical covariates.